Immune Globulin Home Infusion Therapy Part B coverage reminder

**Background:** Amerigroup* reminds providers that the Centers for Medicare & Medicaid Services (CMS) requires that intravenous immune globulin\(^1\) administered in the home setting is only covered under the Medicare Part B benefit when associated with primary immune deficiency disease.\(^1\) Intravenous immune globulin provided for any other diagnosis in the home setting will not be covered under the member’s Part B benefit.

**What this means to you:** Home infusion providers should submit intravenous immune globulin drug reimbursement claims to the members’ Medicare Part D benefit for all indications other than primary immune deficiency disease.

**Additional information and tools**
Please see CMS’ Medicare Prescription Drug Benefit Manual for more information at:

**What if I need assistance?**
If you have questions about this communication, received this fax in error or need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-866-805-4589.

---

*In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc.

---

\(^1\) Immune globulin is defined by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 as an approved pooled plasma derivative: IVIG, SCIG, IMIG.

\(^1\) And meets medical necessity criteria

Amerivantage is an HMO plan with a Medicare contract and a contract with the Texas Medicaid program. Enrollment in Amerivantage depends on contract renewal.